麻豆传媒

Director, Biochemistry and Molecular Biology (BMB) Program
PhD, University of Calcutta, India
Postdoctoral, Albert Einstein College of Medicine, New York
Faculty, Albert Einstein College of Medicine, New York



 

Biography
Tarun Dam started his research in the area of Glycobiology as a graduate student of Professor Amalesh Choudhury. He was trained in the laboratories of Dr. Manju Sarkar (Indian Institute of Chemical Biology, Kolkata) and Professor Avadhesha Surolia (Indian Institute of Science, Bangalore). Dr. Dam joined the Albert Einstein College of Medicine, New York, as a postdoctoral fellow to work with Professor C. Fred Brewer, where he focused on molecular and structural Glycobiology. Dr. Dam joined the faculty of the Albert Einstein College of Medicine after completing his postdoctoral training. Subsequently, he joined the Chemistry Department of Michigan Technological University, where he is now a Professor and the Director of the Biochemistry and Molecular Biology Graduate program. Dr. Dam received several awards including Young Scientist Award, Bhakta Rath Research Award, Distinguished Teaching Award, and Exceptional Mentor Award. Research work in his lab, (the Laboratory of Mechanistic Glycobiology) is focused on (i) the multi-functional and cancer-associated human protein galectin-3, (ii) novel bioactive natural products from plants, and (iii) formulation and validation of new detection/purification methods.



Links of Interest






Research Interests

Molecular basis of glycan (carbohydrate)-mediated biological functions
Glycan binding proteins or lectins
Glycan detection
Mechanistic glycobiology
Macromolecular communication
Biomolecular thermodynamics

Heinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California.
Dr. Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, in 1985. He completed a residency in Hematology and Oncology at the University Hospital Tübingen in Germany, a clerkship in Oncology at George Washington University in Washington, DC, and a clerkship in Hematology at Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in Biochemistry and Molecular Biology at the USC Norris Comprehensive Cancer Center.
An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. He also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Co-Chair of the GI Committee and Correlative Science Committee for SWOG. He is a member of the NCI Task Force for Gastroesophageal Cancer, the NCI Steering Committee and the NCI Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the ASCO Young Investigator Award, the ASCO Career Development Award, and the STOP Cancer Career Development Award. He received in 2021 the USC Mentoring Award as well as highly cited researchers in the world. He has been select as influential leader by the LA Business Journal in 2021 and 2023.
As Deputy Cancer Center Director for Research Programs and Co-Director for the Center for Cancer Drug Development, Dr. Lenz oversees the programmatic and clinical activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women’s Cancers, and Leukemia and Lymphoma Programs.